Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

A private equity firm will finance a Harvard University research lab, a possible template for the future as schools ...

Supernus Pharmaceuticals said it is acquiring Sage Therapeutics, the distressed maker of a drug for postpartum depression, ...

The links between ultra-processed food and higher risk of diabetes will be the focus of the first wave of Kennedy’s national ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a ...

An IVF doctor and clinic founder writes that his industry needs increased governmental oversight and more comprehensive ...

The law shouldn’t force pregnant people to assume greater duties to their fetuses than parents have to their children.

To prevent ovarian cancers, fallopian tube removal is on an upsurge — and diagnostic manuals are finally catching up.

Sarepta said it was halting shipments of its Duchenne gene therapy for patients who can no longer walk, following the death ...

To finance tax cuts, a GOP bill would reduce Medicaid payments to hospitals by $321 billion, hitting both blue and red states ...

If the Senate passes the budget reconciliation bill, one in three adults who work or attend school while enrolled in Medicaid ...

Me, which became a household name for its genetic testing services, is set to emerge from bankruptcy as a nonprofit.